ArticleAnalytical and bioanalytical chemistry2025
Development and clinical application of a novel urinary cortisol extraction agent.
Article in Analytical and bioanalytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Dichloromethane (DCM), a traditional extractant for 24-h urine free cortisol (UFC) testing, poses significant occupational hazards. This study aimed to explore a novel extractant, evaluate its performance in replacing DCM, and establish the biological reference range for UFC detection using the new extractant. Comparative analyses of extraction efficiency were conducted between ethyl acetate (EA) and DCM. A stabilized EA-based formulation (named EEG) was developed by incorporating anhydrous ethanol and gallic acid as anti-hydrolysis and volatility-reducing agents. Recovery rates were assessed using a control product. Stability was tested through delayed detection. Biological reference intervals were determined via chemiluminescence immunoassay (CLIA) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) following EEG extraction, and determined the reference interval using mean ± 1.96 standard deviation. EA demonstrated superior extraction efficiency, yielding significantly higher median cortisol levels (6.27 (IQR 4.68-8.68) µg/dL) versus DCM (3.96 (IQR 2.41-5.07) µg/dL, p = 0.002). Recovery tests confirmed EA's enhanced performance (mean recovery 95.3% vs. DCM's 65.4%, p = 0.011). The EEG formulation exhibited improved stability with unchanged extraction efficacy. Established reference intervals (95% range) were 14.58~136.62 µg/24 h (CLIA) and 0.81~60.55 µg/24 h (LC-MS/MS). EA extraction surpasses DCM in recovery and safety. The optimized EEG formulation demonstrates enhanced stability while maintaining analytical reliability. The newly established reference intervals provide method-specific benchmarks for clinical UFC assessment. This innovation offers a safer, more efficient alternative for routine laboratory practice. The findings underscore the feasibility of replacing hazardous solvents in endocrine diagnostics without compromising analytical performance.
Indexed as
Identifiers
40610812What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.